Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for enoximone (compound)


PubChem
Name: Enoximone
PubChem Compound ID: 53708
Description: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.
Molecular formula: C12H12N2O2S
Molecular weight: 248.302 g/mol
Synonyms:
Fenoximone; Enoximone [USAN:BAN:INN]; Enoximonum [Latin]; 2H-Imidazol-2-one, 1,3-dihydro-4-methyl-5-(4-(methylthio)benzoyl)-; MDL-17043; 77671-31-9; 4-Methyl-5-(p-(methylthio)benzoyl)-4-imidazolin-2-one; RMI-17043; EU-0100410; D04004.
show more »
DrugBank
Identification
Name: Enoximone
Name (isomeric): DB04880
Drug Type: small molecule
Description: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.
Brand: Perfan
Category: Vasodilator Agents, Phosphodiesterase Inhibitors, Cardiotonic Agents
CAS number: 77671-31-9
Pharmacology
Indication: For the treatment of congestive heart failure.
Pharmacology: Enoximone is a phosphodiesterase inhibitor (type III) that increases the force of contraction of the heart and dilates blood vessels. In June 2005, Myogen announced that they were discontinuing development of enoximone due to negative results. The drug is approved for use in the UK.
Mechanism of Action: Further research is required to determine accurately the mechanism of action of drugs with phosphodiesterase inhibitory activity, however, inhibition of PDE3 inhibits degredation of cGMP. This allows for increased NO release and vascular relaxation.
Absorption: Bioavailabvility is 50% following oral administration.
Protein binding: 85%
Biotransformation: Hepatic oxidation
Half Life: 4-10 hours
Affected organisms: Humans and other mammals

Targets